CTIS2023-508083-30-00进行中（未招募）1 期
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, an Anti- TIGIT Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer - GO40290
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •No prior systemic treatment for locally advanced unresectable or metastatic NSCLC, Tumor PD-L1 expression on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening, Confirmed availability of representative tumor specimens, along with an associated pathology report, Measurable disease as defined by RECIST v1.1, Life expectancy =12 weeks, Adequate hematologic and end-organ function
排除标准
- •Patients with NSCLC known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene, Patients with the pulmonary lymphoepithelioma-like carcinoma subtype of NSCLC, Symptomatic, untreated, or actively progressing CNS metastases, Spinal cord compression not definitively treated with surgery and/or radiation, History of leptomeningeal disease, Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and/or treated with expected curative outcome
研究者
相似试验
尚未招募
2 期
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy VolunteersPACTR202012691703415Inovio Pharmaceuticals Inc542
招募中
1 期
Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)Cutaneous Lupus Erythematosus (CLE)MedDRA version: 21.1Level: PTClassification code: 10056509Term: Cutaneous lupus erythematosus Class: 100000004858CTIS2022-501523-24-00Gilead Sciences Inc.33
进行中（未招募）
1 期
A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma).nresectable or metastatic conventional chondrosarcomaMedDRA version: 21.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002635-35-ITInhibrx, INC201
招募中
2 期
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional ChondrosarcomaConventional chondrosarcomas10005959malignant bone tumorNL-OMON54090Inhibrx, Inc.18
进行中（未招募）
1 期
A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma).nresectable or metastatic conventional chondrosarcomaMedDRA version: 21.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002635-35-NLInhibrx, Inc.201